AC IMMUNE SA SF-02 - Asset Resilience Ratio
AC IMMUNE SA SF-02 (IMR) has an Asset Resilience Ratio of 31.65% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMR working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how AC IMMUNE SA SF-02's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AC IMMUNE SA SF-02 total assets.
Liquid Assets Composition Over Time
This chart breaks down AC IMMUNE SA SF-02's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of AC IMMUNE SA SF-02 to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €47.60 Million | 31.65% |
| Total Liquid Assets | €47.60 Million | 31.65% |
Asset Resilience Insights
- Very High Liquidity: AC IMMUNE SA SF-02 maintains exceptional liquid asset reserves at 31.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AC IMMUNE SA SF-02 Industry Peers by Asset Resilience Ratio
Compare AC IMMUNE SA SF-02's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for AC IMMUNE SA SF-02.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.89% | €64.62 Million ≈ $75.54 Million |
€154.25 Million ≈ $180.34 Million |
-14.07pp |
| 2024-12-31 | 55.96% | €129.21 Million ≈ $151.06 Million |
€230.91 Million ≈ $269.96 Million |
+42.53pp |
| 2023-12-31 | 13.43% | €24.55 Million ≈ $28.71 Million |
€182.81 Million ≈ $213.73 Million |
-35.51pp |
| 2022-12-31 | 48.94% | €91.00 Million ≈ $106.39 Million |
€185.94 Million ≈ $217.38 Million |
+4.57pp |
| 2021-12-31 | 44.37% | €116.00 Million ≈ $135.62 Million |
€261.44 Million ≈ $305.65 Million |
-- |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more